Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 15/20 | 0.51 |
| ▸ | JAK2 | O60674 | 13/20 | 0.51 |
| ▸ | JAK1 | P23458 | 13/20 | 0.51 |
| ▸ | CDK19 | Q9BWU1 | 2/20 | 0.43 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.43 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.43 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.43 |
| ▸ | USP1 | O94782 | 1/20 | 0.43 |
| ▸ | WDR48 | Q8TAF3 | 1/20 | 0.43 |
| ▸ | TYK2 | P29597 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15816846 | 0.88 | JAK2 (0.51) | JAK3JAK2JAK1IRAK4TYK2 | |
| SCHEMBL14670597 | 0.88 | JAK2 (0.55) | JAK3JAK2JAK1CDK19ALK | |
| SCHEMBL15817882 | 0.88 | JAK2 (0.55) | JAK3JAK2JAK1CDK19ALK | |
| SCHEMBL14670574 | 0.88 | JAK2 (0.55) | JAK3JAK2JAK1CDK19ALK | |
| SCHEMBL14670599 | 0.88 | JAK2 (0.51) | JAK3JAK2JAK1IRAK4TYK2 | |
| SCHEMBL15817750 | 0.87 | MAP4K1 (0.47) | JAK3JAK2JAK1MAP4K1IRAK4 | |
| SCHEMBL14670533 | 0.87 | MAP4K1 (0.47) | JAK3JAK2JAK1MAP4K1IRAK4 | |
| SCHEMBL14663779 | 0.85 | JAK3 (0.47) | JAK3JAK2JAK1MAP4K1IRAK4 | |
| SCHEMBL14663777 | 0.85 | JAK3 (0.47) | JAK3JAK2JAK1MAP4K1IRAK4 | |
| SCHEMBL14663670 | 0.82 | JAK2 (0.54) | JAK3JAK2JAK1CDK19ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140179664-A1 | Heterocyclyl Pyrimidine Analogues As JAK Inhibitors | CELLZOME LIMITED (GB) | 2014-06-26 | — | — | US | claimed |
| CN-103781780-A | Heterocyclyl pyrimidine analogues as JAK inhibitors | CELLZOME LTD | 2014-05-07 | — | — | CN | claimed |
| US-20140179664-A1 | Heterocyclyl Pyrimidine Analogues As JAK Inhibitors | CELLZOME LIMITED (GB) | 2014-06-26 | — | — | US | disclosed |
| US-20140179664-A1 | Heterocyclyl Pyrimidine Analogues As JAK Inhibitors | CELLZOME LIMITED (GB) | 2014-06-26 | — | — | US | disclosed |
| US-20140179664-A1 | Heterocyclyl Pyrimidine Analogues As JAK Inhibitors | CELLZOME LIMITED (GB) | 2014-06-26 | — | — | US | disclosed |
| CN-103781780-A | Heterocyclyl pyrimidine analogues as JAK inhibitors | CELLZOME LTD | 2014-05-07 | — | — | CN | disclosed |
| WO-2013014162-A1 | HETEROCYCLYL PYRIMIDINE ANALOGUES AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2013-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179664-A1 | Heterocyclyl Pyrimidine Analogues As JAK Inhibitors | JAK1, JAK3, JAK2 | JAK3 2/4885JAK2 3/4885JAK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.